With bucks from Pfizer added to their new round, Amplyx steers a tricky course through PhII and a global pandemic
After beefing up its pipeline last year with an in-licensing deal from Novartis, San Diego-based Amplyx has lined up an extension of their C round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
